Andrew Doan

Andrew Doan is an Assistant Professor of Clinical Pediatrics at the University of Southern California, affiliated with Children’s Hospital Los Angeles (CHLA). His research focuses on pediatric hematology/oncology, particularly immunotherapeutic strategies for hematologic malignancies and genomic characterization of cancers. He investigates treatment efficacy, toxicity, and molecular mechanisms in acute lymphoblastic leukemia (ALL), lymphoma, and other pediatric cancers.

Key research areas include:

• Cancer immunotherapy (e.g., blinatumomab, checkpoint inhibitors)
• Genetic drivers of outcome disparities in ALL
• Impact of SARS-CoV-2 vaccination on immunocompromised pediatric cancer patients
• Molecular profiling of pediatric malignancies using transcriptomics

His work spans translational research, clinical trials, and genomic diagnostics. Notable projects include:

• Evaluating the ABVE-PC chemotherapy regimen for pediatric Hodgkin lymphoma
• Characterizing PAX5 and IKZF1PLUS genetic alterations in leukemia
• Assessing decitabine/vorinostat combinations for relapsed AML

He collaborates with the TACL consortium and employs optical genome mapping for precise molecular analysis. His clinical interests include managing treatment-related toxicities such as methotrexate neurotoxicity and CAR T-cell-related hypogammaglobulinemia.

Publications highlight his contributions to understanding pediatric cancer biology, immunotherapy applications, and genomic approaches to diagnosis and treatment optimization.